Total lymphoid irradiation and anti-thymocyte globulin as conditioning for non-myeloablative allogeneic hematopoietic cell transplantation for the treatment of myelodysplastic syndromes and myeloproliferative disorders (except CML [chronic myeloid leukemia]).
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Antithymocyte globulin (Primary)
- Indications Graft-versus-host disease; Haematological disorders; Myelodysplastic syndromes
- Focus Adverse reactions; Therapeutic Use
- 18 Mar 2015 Biomarkers information updated
- 11 Feb 2011 Planned end date changed from 1 Dec 2012 to 1 Jul 2017 as reported by ClinicalTrials.gov.
- 01 Apr 2009 Planned end date added to 1 Dec 2012 as reported by ClinicalTrials.gov.